Direct-to-Implant Breast Reconstruction

When I began performing direct-to-implant breast reconstruction, implant reconstruction was routinely performed as a two-stage operation. A tissue expander was placed at the time of the mastectomy, and patients returned months later for another operation to remove the expander and replace it with a permanent implant. As skin-sparing and nipple-sparing mastectomy became more successful, I began questioning why every patient needed that second operation.

In many women, the breast skin and nipple were already being preserved. If the remaining skin envelope was healthy and could safely accommodate the desired breast volume, there was often very little that actually needed to be expanded. For example, if a patient ultimately needed a 250-cc implant and I could safely place a tissue expander at approximately that same volume during the first operation, why subject her to months with a temporary device and another surgery simply to exchange it for a 250-cc permanent implant? For patients already facing breast cancer treatment, chemotherapy, and multiple medical procedures, eliminating an unnecessary operation could make a meaningful difference.

That question led me to develop a one-stage approach in which the permanent implant could be placed at the time of the mastectomy and supported immediately. I began performing direct-to-implant reconstruction in 2007 and subsequently published our early experience with the technique.¹ Direct-to-implant reconstruction has evolved considerably since then. Today, I perform most implant reconstruction above the pectoralis muscle and use modern mesh support, objective perfusion assessment, infection-prevention strategies, and a highly structured postoperative protocol. The goal is not simply to put in a permanent implant sooner. The goal is to perform the definitive reconstruction correctly from the beginning.

Why Tissue Expanders Became Less Necessary

Historically, tissue expanders made sense because mastectomy often removed a large amount of skin. Surgeons genuinely needed to recreate a breast envelope before placing a final implant. Skin-sparing and nipple-sparing mastectomy changed that equation. In many patients, the nipple and breast skin are preserved. The breast tissue is removed, but the envelope needed to create the new breast is already present. If the skin is already there, what exactly are we expanding?

When the mastectomy skin is healthy and the implant can appropriately fill the existing breast envelope, there may be no need for a temporary expander at all. Modern systematic reviews have confirmed that DTI reconstruction can be performed with acceptable complication rates in appropriately selected patients.^2,3

Are Tissue Expanders Safer?

Patients are still frequently told that a tissue expander is the “safer” option after mastectomy. I think this deserves a more precise explanation. A tissue expander can give the surgeon flexibility when an area of mastectomy skin is clearly unhealthy and needs to be removed. Its size and shape can be adjusted if the final skin envelope changes unexpectedly. That is different, however, from assuming that a permanent implant automatically places harmful pressure on otherwise healthy mastectomy skin.

I do not believe that a properly selected and well-supported implant inherently causes mastectomy-flap necrosis. We specifically studied this question. In our series of 499 reconstructed breasts, patients whose implants were larger than their mastectomy specimens did not have a higher rate of mastectomy-flap necrosis. Necrosis was actually numerically lower in the upsized group, although the difference was not statistically significant.⁴

This challenges the assumption that placing an implant equal to, or even somewhat larger than, the volume of the original breast necessarily creates harmful pressure on the skin. A breast already occupied that skin envelope before mastectomy. If the reconstruction is appropriately sized and supported, replacing the removed tissue with an implant does not automatically create excessive tension simply because a permanent implant is being used. In our study, implant-to-specimen size difference did not independently predict flap necrosis; flap viability remained the more important issue.⁴

The Quality of the Mastectomy Matters

For me, successful direct-to-implant reconstruction begins before I ever place the implant. It begins with the mastectomy. DTI depends on preserving a healthy, well-perfused skin and nipple envelope, which is why I work closely with breast surgeons who understand that the mastectomy is inseparable from the reconstruction that follows it.

The thickness, blood supply, handling, and preservation of the mastectomy skin all affect the final result. I use intraoperative indocyanine-green angiography to provide an objective assessment of blood flow rather than relying on visual appearance alone. Systematic reviews have found that ICG-guided perfusion assessment can reduce mastectomy-flap necrosis and perfusion-related reoperation compared with clinical assessment alone.⁵ Specific perfusion thresholds are not absolute, but markedly reduced relative perfusion has been associated with a higher likelihood of tissue loss.⁶

This is one reason I believe reconstruction should be viewed as a team procedure rather than two unrelated operations performed by two different surgeons. When the mastectomy skin is healthy, DTI can be extremely predictable. When the skin is genuinely compromised, the safest reconstructive choice may be different. The goal is not to force every patient into a direct-to-implant reconstruction. The goal is to identify when a definitive reconstruction can be performed safely in one operation.

Why I Reconstruct Above the Muscle

Early implant reconstruction was commonly performed beneath the pectoralis major muscle. Over time, it became clear to me that this created several problems that could often be avoided. Placing an implant beneath the pectoralis requires detaching part of the muscle from the chest wall, which can increase postoperative discomfort and create animation deformity, where the implant visibly moves, flattens, pulls upward, or distorts when the pectoralis contracts.

Modern implants and mesh support allow many patients to avoid this entirely. By placing the implant above the muscle, I can preserve the pectoralis in its natural position while controlling the implant with structural mesh instead. This often allows a more natural relationship between the implant and chest wall and avoids muscle-related animation. In patients receiving postmastectomy radiation, recent evidence also suggests that prepectoral placement may reduce the risk of capsular contracture compared with subpectoral placement.⁷

Shape Force: Controlling Breast Shape, Not Just Implant Size

One of the biggest changes I have made in direct-to-implant reconstruction is a technique I call Shape Force. Many implant reconstructions use a standard mesh wrap in which two similarly shaped sheets are placed around the implant. The construct is essentially symmetrical. While this provides coverage and support, it can also encourage a very round breast shape and create a visible ridge or step-off where the upper edge of the implant meets the chest wall.

I began changing the way I constructed the mesh because I wanted greater control over that transition. With Shape Force, the mesh is not simply wrapped uniformly around the implant. It is intentionally tensioned differently in different parts of the breast. I make the construct narrower and more controlled at the upper pole and broader at the lower pole, then secure it to the chest wall at defined fixation points so that the implant maintains its intended position.

This allows me to influence how the implant itself sits. Instead of allowing the implant to determine the final breast shape, I use the mesh to help determine the implant's contour. For a patient who wants a very natural reconstruction, I can create a narrower upper pole and a fuller lower pole, producing a more gradual, teardrop-shaped transition from the chest wall. For a patient who prefers more upper-pole fullness and a rounder breast, the construct can be designed differently.

That means the conversation before surgery is no longer simply about breast size. It can also include breast shape. This is particularly important in thin patients, where there is very little subcutaneous fat over the chest wall and the borders of an implant can be much more visible. Controlling the upper-pole contour can make a significant difference in how natural the reconstruction looks, especially in low-cut clothing. I generally combine Shape Force with a highly moldable implant because the implant itself can respond to the forces created by the mesh. The goal is not to make every reconstructed breast look the same. It is the opposite: Shape Force gives the surgeon and patient more control over the contour of the reconstructed breast, allowing shape, not simply size, to become part of the reconstruction plan.

Structural Support Matters

I prefer structural mesh because I want the implant supported by deeper tissues rather than simply hanging within the mastectomy skin envelope. The purpose of reconstruction is not merely to fill the space where the breast used to be. The implant should be controlled. It should stay where it is intentionally placed and should not progressively descend simply because the overlying skin allows it to.

This is especially important in patients who began with loose or droopy breast skin. The mesh acts as an internal support system, helping establish implant position while also allowing me to control the contour of the reconstruction. In many patients, I want the implant to be more structurally supported than the natural breast was before mastectomy.

A Modern DTI Reconstruction Is a System

Direct-to-implant reconstruction is sometimes described as though the only difference is whether the surgeon places a permanent implant or a tissue expander. That is not how I think about it. Modern DTI in my practice is a system designed to reduce multiple potential sources of complications.

That begins with preservation of the mastectomy skin and continues through implant selection, structural support, perfusion assessment, infection prevention, bleeding reduction, wound management, and postoperative monitoring. Depending on the patient, this may include quantitative perfusion assessment, strict no-touch implant placement, local antibiotic delivery, perioperative tranexamic acid, careful drain management, closed-incision negative-pressure therapy, photobiomodulation, topical treatment to support compromised skin perfusion, hyperbaric oxygen therapy, and additional postoperative treatment directed at threatened mastectomy skin.

Several of these individual strategies have published support. Intravenous tranexamic acid has been associated with a substantial reduction in hematoma after implant-based breast reconstruction, including a large series in which hematoma decreased from 2.9% to 0.46%.⁸ Local antibiotic delivery using absorbable calcium sulfate has been associated with substantially lower infection-related expander or implant loss in published breast-reconstruction series.^9,10 Closed-incision negative-pressure therapy has also been associated with lower wound-complication rates after prosthetic breast reconstruction.^11,12

Photobiomodulation using red or near-infrared light is another component of our postoperative strategy. Experimental skin-flap literature suggests that photobiomodulation may improve microcirculation, angiogenesis, vascular density, and flap viability. A 2024 systematic review found improved flap survival in the large majority of included animal studies.¹³ Proposed mechanisms include effects on mitochondrial signaling, ATP production, nitric oxide signaling, reactive oxygen species, calcium signaling, cellular migration, and tissue repair.¹⁴ In our practice, photobiomodulation is delivered immediately postoperatively as an adjunct intended to support skin perfusion and wound healing.

Topical dimethyl sulfoxide, or DMSO, is another adjunct I use when skin perfusion is a concern. DMSO has been studied clinically in surgical skin flaps, including a prospective randomized mastectomy study in which topical treatment reduced flap-edge necrosis.¹⁵ Additional clinical studies have reported reduced wound-edge necrosis and successful use in threatened nipple-areolar ischemia.^16,17 Proposed mechanisms include vasodilation, inhibition of platelet aggregation within injured microvasculature, antioxidant effects, and modulation of ischemia-reperfusion injury.

Hyperbaric oxygen has an established physiologic rationale and published clinical experience as an adjunct in compromised surgical flaps and ischemic breast-reconstruction tissue.^18–20 By substantially increasing dissolved oxygen in plasma, HBOT can temporarily increase oxygen availability to hypoxic tissue while intrinsic perfusion recovers. It may also reduce edema and support angiogenesis, fibroblast activity, and wound healing.

No single maneuver eliminates complications. What matters is reducing risk at multiple points in the operation and recovery. Some improvements are major changes in technique. Others may improve outcomes only incrementally. But when many small improvements are combined, complications have fewer opportunities to develop.

Who Is a Good Candidate for Direct-to-Implant Reconstruction?

A good candidate for direct-to-implant reconstruction is not defined simply by having a small breast. I have performed DTI reconstruction across a very wide range of breast sizes. What matters more is the relationship between the skin envelope, nipple position, and the volume of the implant being placed.

I think of this as a hand-in-glove fit between the implant and the mastectomy skin. The implant should appropriately fill the available space without leaving excessive empty space around it.

Direct-to-implant reconstruction can work extremely well in smaller-breasted women, and many patients also want to be somewhat larger after reconstruction. If the skin envelope allows it, upsizing can be performed safely. Our implant-sizing study found no increase in mastectomy-flap necrosis when the implant was larger than the mastectomy specimen.⁴ In fact, a small-breasted patient who has extra skin from breastfeeding, pregnancy, weight change, or normal aging may sometimes achieve a better fit with a slightly larger implant than with an implant identical in volume to the original breast. The reason is simple: the implant needs to fill the available envelope appropriately. Too much empty space can create its own problems.

Large-breasted women may also be candidates for DTI. The limiting factor is often not the fact that the breast is large, but whether an implant is available that appropriately matches the desired breast volume and skin envelope. I have successfully performed DTI reconstruction in very large-breasted patients as well.

Nipple Position and Breast Droop Matter More Than Size

A more important limitation is significant breast droop or a very low nipple position. When the nipple position is only mildly low, some natural elevation can occur after mastectomy because the weight of the breast tissue has been removed and the implant is structurally supported. In selected patients, the reconstruction can also be designed so that the nipple and surrounding skin adhere in a somewhat higher position. If a patient is comfortable with a mildly low nipple position, DTI may still be an excellent option.

The challenge comes when a patient wants a substantial breast lift at the same time as reconstruction or when a very large breast is being reduced to a much smaller size. In those situations, the skin envelope may be much larger than the implant being placed, creating a mismatch between the implant and the available skin. The result can be loose skin, dead space, fluid accumulation, and a less predictable breast shape.

For that reason, patients with very low nipples or those who want to become substantially smaller may be better suited to a reconstruction that includes a formal lifting or skin-reduction technique. However, I do not exclude patients based on appearance alone. Each breast has to be evaluated individually. Many patients who initially appear to have too much skin or too much droop can still be candidates for direct-to-implant reconstruction once the skin envelope, nipple position, and desired final breast size are considered together.

The key question is not whether a breast is too small or too large for DTI. It is whether the implant and the mastectomy skin envelope can be matched closely enough to create a stable, well-supported reconstruction.

Does Direct-to-Implant Mean I Will Never Need Another Procedure?

Direct-to-implant reconstruction eliminates the routinely planned expander-to-implant exchange operation, but it does not mean that every patient will choose to have only one surgery in her lifetime.

Some patients are completely satisfied after their initial reconstruction. Others may later choose small refinements, most commonly fat grafting. Fat can be transferred from another area of the body to soften a visible implant edge, improve contour, correct a small asymmetry, or add additional soft-tissue coverage in a thin patient.

I consider this very different from a planned tissue-expander exchange. With a traditional two-stage reconstruction, the second operation is built into the treatment because the expander is temporary and must ultimately be replaced. With DTI, the implant placed at the mastectomy is intended to be the definitive implant. Any later procedure is based on the patient's anatomy, healing, or aesthetic goals rather than being an obligatory stage of reconstruction.

One of the goals of Shape Force is to create as smooth an upper-pole transition as possible during the initial reconstruction, potentially reducing the contour irregularities that often lead surgeons to recommend secondary fat grafting. This is a goal of the technique rather than a formally proven reduction in fat-grafting rates.

Direct-to-Implant Does Not Mean One Size Fits All

DTI is not appropriate for every patient. If the mastectomy skin is significantly compromised, if the nipple position requires a major lift, if the patient wants a very large reduction in breast volume, or if the skin envelope and desired implant cannot be matched reliably, another reconstruction may provide a better result. Those options may include a skin-reducing reconstruction, SWIM flap reconstruction, staged reconstruction, or another individualized approach.

The goal is never to perform DTI simply because it can be done. The goal is to choose the reconstruction that gives the patient the safest operation and the best long-term breast.

Nearly Two Decades of Evolution

My approach to direct-to-implant reconstruction has continued to evolve since I began performing it in 2007. The major changes have included eliminating the routine tissue-expander stage, developing immediate permanent-implant reconstruction, transitioning from subpectoral to prepectoral implant placement, increasing collaboration with mastectomy surgeons to protect flap viability, using quantitative intraoperative perfusion assessment, incorporating structural mesh support, developing Shape Force to control breast contour, improving infection-prevention strategies, adding advanced wound-management and perfusion-support techniques, and studying implant sizing and mastectomy-flap necrosis.

Some of the biggest improvements have come from major changes in technique. Others have come from many smaller decisions that each improve the odds by a little bit. Together, they have changed what direct-to-implant reconstruction can look like and how predictable it can become.

The Goal

Direct-to-implant reconstruction is not simply about avoiding a second surgery. It is about creating a definitive breast reconstruction from the beginning. That requires protecting the mastectomy skin, choosing the correct implant, controlling its position, controlling its shape, reducing preventable complications, and tailoring the reconstruction to the individual patient.

When all of those elements come together, the result can be a breast that is stable, supported, natural in appearance, and designed to remain that way long after the mastectomy is over.